Union Bancaire Privee UBP SA Grows Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Union Bancaire Privee UBP SA grew its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 16.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 29,765 shares of the medical research company’s stock after buying an additional 4,249 shares during the quarter. Union Bancaire Privee UBP SA’s holdings in Thermo Fisher Scientific were worth $13,605,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of TMO. Canoe Financial LP increased its stake in Thermo Fisher Scientific by 92.5% during the second quarter. Canoe Financial LP now owns 309,994 shares of the medical research company’s stock worth $155,419,000 after purchasing an additional 148,999 shares during the period. Davis Capital Management grew its holdings in shares of Thermo Fisher Scientific by 15,150.0% in the second quarter. Davis Capital Management now owns 610 shares of the medical research company’s stock valued at $306,000 after purchasing an additional 606 shares in the last quarter. Highline Wealth Partners LLC increased its stake in Thermo Fisher Scientific by 60.3% during the 2nd quarter. Highline Wealth Partners LLC now owns 109 shares of the medical research company’s stock worth $55,000 after buying an additional 41 shares during the period. Bell Bank lifted its holdings in Thermo Fisher Scientific by 9.1% during the 2nd quarter. Bell Bank now owns 563 shares of the medical research company’s stock worth $282,000 after buying an additional 47 shares in the last quarter. Finally, Prospera Financial Services Inc boosted its position in Thermo Fisher Scientific by 11.6% in the 2nd quarter. Prospera Financial Services Inc now owns 16,946 shares of the medical research company’s stock valued at $8,499,000 after buying an additional 1,763 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 420 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $584.81, for a total transaction of $245,620.20. Following the sale, the chief accounting officer owned 2,966 shares of the company’s stock, valued at approximately $1,734,546.46. This trade represents a 12.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael D. Shafer sold 25,500 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the sale, the executive vice president owned 20,994 shares of the company’s stock, valued at $12,596,400. This represents a 54.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 52,053 shares of company stock valued at $30,643,589 over the last three months. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $588.17 on Friday. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $643.99. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. The company has a market cap of $217.47 billion, a P/E ratio of 31.64, a PEG ratio of 2.39 and a beta of 0.85. The firm has a fifty day moving average price of $529.37 and a 200 day moving average price of $509.58.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The company had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same period in the previous year, the business earned $4.28 EPS. Thermo Fisher Scientific’s revenue for the quarter was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be issued a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is 10.11%.

Analysts Set New Price Targets

A number of research firms have recently weighed in on TMO. Barclays upped their price objective on Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. Robert W. Baird lowered their target price on Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Weiss Ratings upgraded Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, July 14th. Morgan Stanley lifted their price objective on Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an “overweight” rating in a research note on Friday, July 24th. Finally, KeyCorp reissued an “overweight” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average price target of $619.41.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.